Neurocrine Biosciences
NBIX
HK$1,013
Share price
-0.22%
Change (1 day)
-6.73%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Total assets
Total assets on the balance sheet as of March 2025 : HK$28.94 Billion
According to Neurocrine Biosciences 's latest financial reports the company's total assets are HK$28.94 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Neurocrine Biosciences - Total assets on balance sheet (from 2001 to 2025)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | HK$28.87 B | 13.69% |
| 2023-12-31 | HK$25.39 B | 37.21% |
| 2022-12-31 | HK$18.50 B | 14.52% |
| 2021-12-31 | HK$16.16 B | 20.17% |
| 2020-12-31 | HK$13.44 B | 32.21% |
| 2019-12-31 | HK$10.17 B | 30.78% |
| 2018-12-31 | HK$7.77 B | 21.75% |
| 2017-12-31 | HK$6.38 B | 125.63% |
| 2016-12-31 | HK$2.83 B | -23.07% |
| 2015-12-31 | HK$3.67 B | 95.21% |
| 2014-12-31 | HK$1.88 B | 57.17% |
| 2013-12-31 | HK$1.19 B | -21.04% |
| 2012-12-31 | HK$1.51 B | 41.35% |
| 2011-12-31 | HK$1.07 B | -4.38% |
| 2010-12-31 | HK$1.12 B | 104.69% |
| 2009-12-31 | HK$0.54 B | -39.87% |
| 2008-12-31 | HK$0.91 B | -57.66% |
| 2007-12-31 | HK$2.15 B | -28.83% |
| 2006-12-31 | HK$3.03 B | -19.09% |
| 2005-12-31 | HK$3.74 B | -7.17% |
| 2004-12-31 | HK$4.03 B | -6.2% |
| 2003-12-31 | HK$4.30 B | 106.94% |
| 2002-12-31 | HK$2.07 B | -23.03% |
| 2001-12-31 | HK$2.70 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | HK$22.38 B | -22.66% | 🇺🇸 USA |
 Royalty Pharma RPRX | HK$138.21 B | 377.49% | 🇬🇧 UK |
 Palatin Technologies PTN | HK$29.26 M | -99.90% | 🇺🇸 USA |
 Eli Lilly LLY | HK$701.66 B | 2,323.97% | 🇺🇸 USA |
 AbbVie ABBV | HK$1.068 T | 3,592.41% | 🇺🇸 USA |
 Pfizer PFE | HK$1.632 T | 5,541.13% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | HK$10.14 B | -64.95% | 🇺🇸 USA |
 Athersys ATHX | HK$58.3 M | -99.80% | 🇺🇸 USA |